Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs00920304
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
---|---|---|---|---|---|
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
IX1 | 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)- 4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID | A | 1XBO | 0.71 | |
105 | N-[5-METHYL-3-O-TOLYL-ISOXAZOLE- 4-CARBOXYLIC ACID AMIDE] BORONIC ACID | A | 1JWZ | 0.74 | |
105 | N-[5-METHYL-3-O-TOLYL-ISOXAZOLE- 4-CARBOXYLIC ACID AMIDE] BORONIC ACID | A,B | 1FSY | 0.74 | |
105 | N-[5-METHYL-3-O-TOLYL-ISOXAZOLE- 4-CARBOXYLIC ACID AMIDE] BORONIC ACID | A | 1NYY | 0.74 | |
2GJ | 5-[2,4-DIHYDROXY-5-(1-METHYLETHYL)PHENYL]- N-ETHYL-4-[4-(MORPHOLIN-4-YLMETHYL)PHENYL]ISOXAZOLE- 3-CARBOXAMIDE | A | 2VCI | 0.87 | |
AG7 | 4-{2-(4-FLUORO-BENZYL)-6-METHYL- 5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)- AMINO]-4-OXO-HEPTANOYLAMINO}-5- (2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER | A | 1CQQ | 0.8 | |
4PR | (3S)-1-{[(3,5-DIMETHYLISOXAZOL- 4-YL)AMINO]CARBONYL}-4,4-DIMETHYLPYRROLIDIN- 3-YL{(1S)-1-[1-HYDROXY-2-OXO-2- {[(1R)-1-PHENYLETHYL]AMINO}ETHYL]PENTYL}CARBAMATE | A | 2BDL | 0.72 | |
ANY | 2-METHYL-BUTYRIC ACID 3-(3-FORMYLAMINO- 2-HYDROXY-BENZOYLAMINO)-8-HEPTYL- 2,6-DIMETHYL-4,9-DIOXO-[1,5]DIOXONAN- 7-YL ESTER | A,C,D,E,N,P, Q,R | 3H1I | 0.71 | |
ANY | 2-METHYL-BUTYRIC ACID 3-(3-FORMYLAMINO- 2-HYDROXY-BENZOYLAMINO)-8-HEPTYL- 2,6-DIMETHYL-4,9-DIOXO-[1,5]DIOXONAN- 7-YL ESTER | A,B,C,D,E,F, G,O,P,Q,R,S,T | 1PPJ | 0.71 | |
VRS | VIRGINIAMYCIN S1 | 0,1,2,3,9,A, B,C,H,J,K,L, M,N,O,Q,R,S, T,U,Y,Z | 1YIT | 0.72 | |
234 | 5-{2-FLUORO-5-[3-(3-HYDROXY-2-METHOXYCARBONYL- PHENOXY)-PROPENYL]-PHENYL}-ISOXAZOLE- 3-CARBOXYLIC ACID | A | 1Q1M | 0.72 | |
AMY | ANTIMYCIN | C,D,E | 3BCC | 0.71 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A | 2HOB | 0.8 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A,B | 2AMQ | 0.8 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A,B,C,D | 3D23 | 0.8 | |
3IH | N-[(5-METHYLISOXAZOL-3-YL)CARBONYL]ALANYL- L-VALYL-N~1~-((1R,2Z)-4-(BENZYLOXY)- 4-OXO-1-{[(3R)-2-OXOPYRROLIDIN- 3-YL]METHYL}BUT-2-ENYL)-L-LEUCINAMIDE | A,B | 2Q6F | 0.8 | |
ANJ | (2R,3S,6S,7R,8R)-3-{[3-(FORMYLAMINO)- 2-HYDROXYBENZOYL]AMINO}-8-HEXYL- 2,6-DIMETHYL-4,9-DIOXO-1,5-DIOXONAN- 7-YL (2S)-2-METHYLBUTANOATE | A,B,C,D,E,F, G,H,I,J,K,L | 2QJP | 0.71 | |
ANJ | (2R,3S,6S,7R,8R)-3-{[3-(FORMYLAMINO)- 2-HYDROXYBENZOYL]AMINO}-8-HEXYL- 2,6-DIMETHYL-4,9-DIOXO-1,5-DIOXONAN- 7-YL (2S)-2-METHYLBUTANOATE | A,B,C,D,E,F, G,H,I,J,K,L, M,N,O,P,Q,R | 2QJK | 0.71 | |
2GG | 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)- N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE- 3-CARBOXAMIDE | A | 2UWD | 0.8 | |
GNI | (3-{4-[2-(2,4-DICHLORO-PHENOXY)- ETHYLCARBAMOYL]-5-PHENYL-ISOXAZOL- 3-YL}-PHENYL)-ACETIC ACID | A,B | 2J14 | 0.72 | |
19B | 4-methyl-N-(3-morpholin-4-ylphenyl)- 3-(3-piperidin-4-yl-1,2-benzisoxazol- 6-yl)benzamide | A | 3E93 | 0.72 | |
SOY | OXACILLIN-ACYLATED SERINE | A | 2IWD | 0.77 | |
272 | 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3- YL)BENZENE-1,3-DIOL | A,B,C,D | 1U3Q | 0.73 | |
CY6 | N-((3S,6R)-6-((S,E)-4-ETHOXYCARBONYL- 1-((S)-2-OXOPYRROLIDIN-3-YL)BUT- 3-EN-2-YLCARBAMOYL)-2,9-DIMETHYL- 4-OXODEC-8-EN-3-YL)-5-METHYLISOXAZOLE- 3-CARBOXAMIDE | A | 2ALV | 0.71 | |
CXZ | 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]- 1,2-benzisoxazol-3-yl}benzene-1,3- diol | A | 3BMY | 0.74 | |
2EQ | 5-(5-chloro-2,4-dihydroxyphenyl)- N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole- 3-carboxamide | A | 2VCJ | 0.82 |